Ventolin HFA Alternatives Compared
| Ventolin HFA (albuterol) | Xolair (omalizumab) | Dupixent (dupilumab) |
|
|---|
| Ventolin HFA (albuterol) | Xolair (omalizumab) | Dupixent (dupilumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Asthma - acute, Bronchiectasis, Asthma - Maintenance, COPD - Acute, Bronchospasm Prophylaxis, COPD - Maintenance. Ventolin HFA may also be used for purposes not listed in this medication guide. View more |
Prescription only
Xolair is an injectable preparation that works by preventing IgE from binding to IgE receptors on mast cells and basophils and may be used to treat allergic asthma, nasal polyps, chronic idiopathic... View more |
Prescription only
Dupixent injection is usually given every 1 to 4 weeks to treat asthma, eczema, chronic rhinosinusitis, COPD, eosinophilic esophagitis, or prurigo nodularis. Injection site reactions and eye problems... View more |
Related suggestions Asthma, Maintenance
|
|||||||||||||||
| More about Ventolin HFA (albuterol) | More about Xolair (omalizumab) | More about Dupixent (dupilumab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Ventolin HFA has an average rating of 7.5 out of 10 from a total of 18 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 11% reported a negative effect. |
Xolair has an average rating of 7.5 out of 10 from a total of 229 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 18% reported a negative effect. |
Dupixent has an average rating of 7.2 out of 10 from a total of 498 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Ventolin HFA side effects |
View all Xolair side effects |
View all Dupixent side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Ventolin HFA prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Dupixent prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Other albuterol brands include: ProAir HFA, ProAir RespiClick, Proventil HFA, Ventolin, Vospire ER | Other omalizumab brands include: Omlyclo |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
6.5 hours |
624 hours |
N/A |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 424 drugs are known to interact with Ventolin HFA:
|
A total of 28 drugs are known to interact with Xolair:
|
A total of 92 drugs are known to interact with Dupixent:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
April 19, 2001 |
June 20, 2003 |
March 28, 2017 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.